Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Park, Won ^a   Yoo, Dae Hyun ^b   Jaworski, Janusz ^c   Brzezicki, Jan ^d   Gnylorybov, Andriy ^e   Kadinov, Vladimir ^f   Sariego, Irmgadt Goecke ^g   Abud Mendoza, Carlos ^h   Escalante, William Jose Otero ⁱ   Kang, Seong Wook ^j   Andersone, Daina ^k   Blanco, Francisco ^l   Hong, Seung Suh ^m   Lee, Sun Hee ^m   Braun, Jürgen ⁿ  

^a Inha University Hospital   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c Linea Corporis   (Poland)

^d Wojewodzki Szpital Zespolony w Elblagu   (Poland)

^e Institute of Urgent and Recovery Surgery   (Ukraine)

^f UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^g Prosalud y Cia Ltda   (Chile)

^h HOSPITAL CENTRAL DR IGNACIO MORONES PRIETO   (Mexico)

ⁱ Servimed Empresa Unipersonal   (Colombia)

^j Chungnam National University College of Medicine   (South Korea)

^k PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^l UNIVERSITY OF A CORUÑA   (Spain)

^m Celltrion Inc   (South Korea)

ⁿ RHEUMAZENTRUM RUHRGEBIET   (Germany)

more..

Author keywords

Ankylosing spondylitis; ASAS; Biosimilar; Clinical trial; CT P13; Efficacy; Immunogenicity; Infliximab; Pharmacokinetics; Safety

Indexed keywords

ANTIINFLAMMATORY AGENT; CT P 13; INFLIXIMAB; PLACEBO; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOSIMILAR AGENT; CT-P13; MONOCLONAL ANTIBODY;

ADOLESCENT; AGED; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HERPES VIRUS INFECTION; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; LATENT TUBERCULOSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NEUTROPENIA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SHORT FORM 36; SINUSITIS; TREATMENT DURATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADULT; CHEMICALLY INDUCED; CLINICAL TRIAL; INTERNATIONAL COOPERATION; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; SELF REPORT; SPONDYLITIS, ANKYLOSING; STANDARDS; TOXIC HEPATITIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOSIMILAR PHARMACEUTICALS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLIXIMAB; INTERNATIONALITY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUTROPENIA; SELF REPORT; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954568420     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-0930-4     Document Type: Article

References (32)

1. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187-93.
2. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582-91.
3. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:905-8.
4. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896-904.
5. Nast A, Mrowietz U, Kragballe K, de Jong EM, Puig L, Reich K, et al. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis-a multinational cross-sectional study. Arch Dermatol Res. 2013;305:899-907.
6. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198-206.
7. World Health Organization. Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. Available at: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 19 Feb 2015.
8. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab). 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf. Accessed 19 Feb 2015.
9. Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, et al. Physicochemical characterization of Remsima®. mAbs. 2014;6:1163-77.
10. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Similar Biological Medicine Products (CHMP/437/04 Rev 1). 23 October 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 2 July 2015.
11. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. April 2015. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 2 July 2015.
12. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613-20.
13. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605-12.
14. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-8.
15. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:2224-33.
16. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 2008;58:88-97.
17. Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30:1437-40.
18. Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Tobias-Arteaga E, Baranauskaite A, et al. A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study. Ann Rheum Dis. 2013;72 Suppl 3:73 [OP0068].
19. US Food and Drug Administration. Infliximab Product Approval Information: Clinical Pharmacology Review 1999; Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107725.pdf. Accessed 20 Feb 2015
20. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-63.
21. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1075-86.
22. Zhang F-C, Hou Y, Huang F, Wu D-H, Bao C-D, Ni L-Q, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol. 2006;9:127-30.
23. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol. 2006;33:37-44.
24. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602.
25. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096-103.
26. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43.
27. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27-35.
28. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'Connor P, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis. 2005;64:1568-75.
29. Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002;46:755-65.
30. Plasencia C, Pascual-Salcedo D, Nuno L, Bonilla G, Villalba A, Peiteado D, et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71:1955-60.
31. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711-5.
32. Baert F, Noman M, Vermeire S, Van Assche G, DH G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-8.